GlobeNewswire Press

  1. Novavax Acquires New Manufacturing And Office Facilities In Gaithersburg, MD
    11/23/2011
    Novavax, Inc. today announced that it has entered a long-term lease arrangement for 74,000-square-feet of manufacturing, lab and office space in two facilities in Gaithersburg, MD.
  2. Momenta Pharmaceuticals Obtains Preliminary Injunction Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. And International Medical Systems, Ltd.
    11/1/2011
    Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the United States District Court for the District of Massachusetts today entered an order enjoining Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd. from offering to sell or selling their generic Lovenox™ before the District Court renders a decision in the on-going litigation relating to the U.S. Patent No. 7,575,886.
  3. RXi Pharmaceuticals® To Strengthen Strategic Focus By Separating Into Two Publicly Traded Companies
    9/27/2011
    RXi Pharmaceuticals Corporation (Nasdaq:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, today reported that it will separate its programs into two publicly traded companies: Galena Biopharma will focus on the development of targeted cancer therapies; and RXi Pharmaceuticals will focus on the development of RNAi-based therapeutics.
  4. RXi Pharmaceuticals Licenses Novel, Targeted Cancer Vaccine For Gynecological Cancers
    9/22/2011
    RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it licensed worldwide rights to develop and commercialize a Folate Binding Protein-E39 (FBP) targeted vaccine to prevent recurrence in gynecological cancers such as ovarian and endometrial adenocarcinomas.
  5. Progenics Pharmaceuticals Announces Strategic Focus On Oncology
    9/20/2011
    Progenics Pharmaceuticals, Inc. today announced strategic, operational, organizational and financial changes resulting from a review of its business.
  6. RXi Pharmaceuticals Provides Positive NeuVax™ Phase 3 Clinical Trial Update
    9/13/2011
    RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, today announced a clinical trial update on its lead program, NeuVax™ (E75 peptide vaccine with GM-CSF adjuvant), a cancer immunotherapy targeted for low-to-intermediate HER2 expressing breast cancer patients not eligible for trastuzamab (Herceptin®).
  7. Bohai Pharmaceuticals Makes Important Acquisition Of Rapidly Growing TCM Company In China
    8/15/2011
    Bohai Pharmaceuticals Group, Inc. (OTCBB:BOPH) (OTCQB:BOPH), today announced that it has consummated a significant acquisition of a complementary Traditional Chinese Medicine (TCM) company in China, Yantai Tianzheng Pharmaceutical Co., Ltd. Like Bohai, Yantai Tianzheng produces, manufactures and distributes modernized herbal medicines based on TCM in China.
  8. Sagent Pharmaceuticals Announces FDA Approval Of Polymyxin B For Injection, USP
    7/5/2011
    Sagent Pharmaceuticals, Inc. today announced U.S. FDA approval of polymyxin B for injection, USP, an antibacterial drug, in 500,000 units per vial, latex-free glass vials.
  9. Ventrus Announces Improved, FDA-Recommended Endpoints Proposed For Phase III Hemorrhoid Study
    3/22/2011
    Ventrus BioSciences, Inc. (Nasdaq:VTUS) has filed a revised protocol with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) with new, more robust definitions for efficacy endpoints that were recommended by the FDA in a recent meeting with the company for the first pivotal study of the company's iferanserin (VEN 309) ointment, the first prescription product candidate for the treatment of hemorrhoids.

First 1 1 (Last)